Global Footprint CordenPharma is expanding its peptide focused CDMO footprint with new production sites in the United States and China and by acquiring AmbioPharm facilities, strengthening global peptide API capacity and regional supply resilience.

Peptide Leadership A strong emphasis on GLP-1 and peptide APIs positions CordenPharma as a leading partner for customers seeking scalable peptide manufacturing, backed by ongoing capacity expansion.

Integrated CDMO Platform The six technology platforms enable end to end development through manufacturing and packaging, offering clients a single integrated path for APIs, lipids and excipients, oligonucleotides, injectables, highly potent oncology products and small molecules.

Compliance Readiness A network of cGMP facilities across Europe and the US supported by modern IT and security frameworks indicates robust quality, data integrity and regulatory readiness for global collaborations.

Financial Scale With a large revenue base and a track record of strategic investments and ownership, CordenPharma presents a compelling platform for large, long term partnerships in pharma manufacturing.